These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1128 related articles for article (PubMed ID: 15570007)

  • 1. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
    Narayanan BA; Narayanan NK; Pittman B; Reddy BS
    Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
    Narayanan BA; Narayanan NK; Pttman B; Reddy BS
    Prostate; 2006 Feb; 66(3):257-65. PubMed ID: 16175586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
    Narayanan BA; Reddy BS; Bosland MC; Nargi D; Horton L; Randolph C; Narayanan NK
    Clin Cancer Res; 2007 Oct; 13(19):5965-73. PubMed ID: 17908994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
    Raina K; Blouin MJ; Singh RP; Majeed N; Deep G; Varghese L; Glodé LM; Greenberg NM; Hwang D; Cohen P; Pollak MN; Agarwal R
    Cancer Res; 2007 Nov; 67(22):11083-91. PubMed ID: 18006855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors.
    Narayanan NK; Narayanan BA; Reddy BS
    Int J Oncol; 2005 Mar; 26(3):785-92. PubMed ID: 15703837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations.
    Shibata MA; Ward JM; Devor DE; Liu ML; Green JE
    Cancer Res; 1996 Nov; 56(21):4894-903. PubMed ID: 8895741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells.
    Andrews J; Djakiew D; Krygier S; Andrews P
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):277-84. PubMed ID: 12357301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
    Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
    Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and role of Foxa proteins in prostate cancer.
    Mirosevich J; Gao N; Gupta A; Shappell SB; Jove R; Matusik RJ
    Prostate; 2006 Jul; 66(10):1013-28. PubMed ID: 16001449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
    Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
    Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
    Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
    Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer.
    Basu GD; Pathangey LB; Tinder TL; Lagioia M; Gendler SJ; Mukherjee P
    Mol Cancer Res; 2004 Nov; 2(11):632-42. PubMed ID: 15561779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
    Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
    Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion.
    Man YG; Gardner WA
    Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Akt GSK-3 pathway as a target in genistein-induced inhibition of TRAMP prostate cancer progression toward a poorly differentiated phenotype.
    El Touny LH; Banerjee PP
    Carcinogenesis; 2007 Aug; 28(8):1710-7. PubMed ID: 17468512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue.
    Wang X; Colby JK; Yang P; Fischer SM; Newman RA; Klein RD
    Carcinogenesis; 2008 Jan; 29(1):120-8. PubMed ID: 17942462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells.
    Lim JT; Piazza GA; Pamukcu R; Thompson WJ; Weinstein IB
    Clin Cancer Res; 2003 Oct; 9(13):4972-82. PubMed ID: 14581372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo.
    Adhami VM; Malik A; Zaman N; Sarfaraz S; Siddiqui IA; Syed DN; Afaq F; Pasha FS; Saleem M; Mukhtar H
    Clin Cancer Res; 2007 Mar; 13(5):1611-9. PubMed ID: 17332308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.
    Gupta S; Adhami VM; Subbarayan M; MacLennan GT; Lewin JS; Hafeli UO; Fu P; Mukhtar H
    Cancer Res; 2004 May; 64(9):3334-43. PubMed ID: 15126378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
    Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
    J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.